NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
23/03/2019
Voltar para busca
Dado oficial do USPTO
MOFFITT CANCER CENTER M
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
13/05/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
16, 41, 42, 44
Data de depósito
22/02/2008
Data de registro
25/08/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/03/2019
Última transação
13/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Primeiro uso
30/11/2007
Primeiro uso no comércio
30/11/2007
Código do desenho
3
Tipo de titular
03
Localização do titular
Tampa, FL
Examinador
BUJA, SANDRA
Unidade examinadora
L40
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Representantes
Corey K. Cho Saliwanchik, Lloyd & Eisenschenk, P.A.
Classificação técnica
Classes Nice
Classe 16Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 16
Publicationsprinted instructional and teaching materialsbrochurespamphletsbulletinsnewsletters and magazinesall in the field of health carecancer protectionpreventiondetection and treatmentmedical diagnostics and prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases
Classe 41
Medical educational servicesconducting lecturesseminars and workshops to health care practitionerspatients and patient caregivers in the field of health carecancer care and prevention of cancermedical diagnosticsprognostics and the evaluation of drug and treatment effectiveness relating to cancer and other diseases
Classe 42
Providing an online database and depository for the collection of clinical and molecular data derived from a patient that is accessible by physicianspatients and researchersan online database in the field of human clinical and molecular data accumulation and analysis for aiding medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases for research purposes; medical and clinical research resources in the field of cancer and other diseasesproviding data regarding tumor-specific molecular signatures and the effectiveness of a drug and/or diagnostic test for research purposes; medical and clinical research resources in the field of cancer and other diseasesproviding evidence-based treatment protocols by effectively comparing standard treatment therapies with clinical outcomes for research purposes; medical research services consisting of collection and analysis of data in the field of human clinical and molecular data for aiding medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseasesmatching particular patients to a particular drugtreatmenttherapy or clinical trial by the specific molecular signature of the patient; collection and analysis of data services in the field of human clinical and molecular data accumulation and analysis for research assistance for medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseasesproviding objective data in usable form on the effectiveness of a drug or diagnostic test
Classe 44
Providing health caremedical information and counseling in the field of cancer; providing medical screening and diagnostic services with use of patient scanning equipment; providing an online computer database featuring medical information in the field of human clinical and molecular data accumulation and analysis for aiding medical diagnosticsprognostics and the evaluation and testing of drug and treatment effectiveness; medical servicescancer care and prevention of cancermedical diagnosticsprognostics and evaluation of drug and treatment effectiveness relating to cancer and other diseases; medical counseling; telephone hot line counselingoffering advice regarding cancer preventiondetectiontreatment and clinical testing in the field of cancer and other diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
23/03/2019
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
23/03/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
20/03/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
07/03/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
25/08/2018
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
23/12/2014
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
22/12/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
22/12/2014
E815
TEAS SECTION 8 & 15 RECEIVED
03/12/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/07/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
25/08/2009
PUBO
PUBLISHED FOR OPPOSITION
09/06/2009
NPUB
NOTICE OF PUBLICATION
20/05/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/05/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/04/2009
XAEC
EXAMINER'S AMENDMENT ENTERED
29/04/2009
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
29/04/2009
GNEA
EXAMINERS AMENDMENT E-MAILED
29/04/2009
CNEA
EXAMINERS AMENDMENT -WRITTEN
29/04/2009
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
28/04/2009
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
13/04/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/04/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/03/2009
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/03/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/03/2009
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/03/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
18/02/2009
GNRT
NON-FINAL ACTION E-MAILED
18/02/2009
CNRT
NON-FINAL ACTION WRITTEN
18/02/2009
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/01/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/01/2009
ALIE
ASSIGNED TO LIE
22/01/2009
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/12/2008
ALIE
ASSIGNED TO LIE
17/12/2008
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/12/2008
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/12/2008
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2008
CNRT
NON-FINAL ACTION MAILED
16/06/2008
CNRT
NON-FINAL ACTION WRITTEN
14/06/2008
DOCK
ASSIGNED TO EXAMINER
04/06/2008
MAFR
APPLICATION FILING RECEIPT MAILED
04/03/2008
NWAP
NEW APPLICATION ENTERED
28/02/2008
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MOFFITT CANCER CENTER M ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.